Catecholamine receptors: prototypes for GPCR-based drug discovery.
Drugs acting at G protein-coupled receptors (GPCRs) constitute ~40% of those in current clinical use. GPCR-based drug discovery remains at the forefront of drug development, especially for new treatments for psychiatric illness and neurological disease. Here, the basic framework of GPCR signaling learned through the elucidation of catecholamine receptor signaling through G proteins and β-arrestins, and X-ray crystallographic structure determination is reviewed. In silico docking studies developed in tandem with confirmatory empirical data gathering from binding and signaling experiments have allowed this basic framework to be expanded to drug hunting through predictive in silico searching as well as high-throughput and high-content screening approaches. For efforts moving forward for the deployment of new GPCR-acting drugs, collaborative efforts between industry and government/academic research in target validation at the molecular and cellular levels have become progressively more common. Polypharmacological approaches have become increasingly available for learning more about the mechanisms of GPCR-targeted drugs, based on interaction not with a single, but with a wide range of GPCR targets. These approaches are likely to aid in drug repurposing efforts, yield valuable insight on the side effects of currently employed drugs, and allow for a clearer picture of the actual targets of "atypical" drugs used in a variety of therapeutic contexts.
Section on Molecular Neuroscience, Laboratory of Cellular and Molecular Regulation, National Institute of Mental Health Intramural Research Program, Bethesda, Maryland, USA. Electronic address: andrew.emery@nih.gov.
Andrew C
AC
Emery
D000818:Animals; D055808:Drug Discovery; D006801:Humans; D008024:Ligands; D017983:Receptors, Catecholamine / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism
D008024:Ligands; D017983:Receptors, Catecholamine; D043562:Receptors, G-Protein-Coupled
Drug discovery; GPCR; HTS; Ligand bias; Signaling